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In this paper we demonstrate that human platelets contain an acylphosphatase isoenzyme. We then investigated the effect 
of exogenously added human muscle and erythrocyte acylphosphatases on inositol lipid content in human platelets per- 
meabilized with saponin. Alterations in the level of the polyphosphoinositides were observed: in particular, the levels 
of phosphatidylinositol 4,5_bisphosphate, and of phosphatidylinositol 4-monophosphate were decreased, whereas the 
level of phosphatidylinositol was increased. These results suggest that acylphosphatases promote polyphosphoinositide 
dephosphorylation, possibly through intracellular Ca2+ mobilization. 
Inositol lipid; Platelet; Acylphosphatase 
1. INTRODUCTION 
It is well known that muscle acylphosphatase 
(EC 3.6.1.7) catalyzes the hydrolysis of 
acylphosphates in solution and bound to mem- 
brane proteins in several vertebrate species; ex- 
amples of this activity include the Na+,K+ and 
Ca2+,Mg2+-dependent ATPases [ 1,2]. Recently, a 
novel acylphosphatase has been purified and se- 
quenced from human erythrocytes. Although 
similar in molecular mass, this enzyme exhibits 
greater than 50% variability in amino acid residues 
when compared to the muscle isoenzyme; however, 
the kinetic parameters are very similar [3]. The two 
acylphosphatases are differently distributed in 
organs and tissues in different species: in horse, the 
muscular form is abundant in skeletal muscle, 
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heart, and brain, although lower amounts were 
found in liver, kidney and erythrocytes [4]; on the 
other hand, in human the erythrocyte form is more 
abundant in brain, erythrocytes and blood 
platelets. The content of the muscular form in 
platelets has not been determined as yet. 
Permeabilization of human platelets with 
saponin has recently been used to investigate the 
effect of various compounds on inositol lipid 
metabolism and protein phosphorylation [S-lo]. 
In the present study we describe the effect of ex- 
ogenously added acylphosphatases on inositol lipid 
metabolism and protein phosphorylation in intact 
and permeabilized platelets. 
2. EXPERIMENTAL 
Acylphosphatases were purified from human muscle (-SH 
form) and erythrocytes as previously reported [3,11- 131. 
Acylphosphatase activity was determined by continuous optical 
test at 238 nm using benzoylphosphate as substrate, according 
to Ramponi et al. [14]. Saponin was purchased from Merck; 
carrier-free “P-orthophosphate was from Amersham; pre- 
coated silica gel plates were from Whatman; phos- 
phatidylinositol 4,5-bisphosphate (PIPz) and thrombin were 
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from Sigma; [‘HIPIP was from New England Nuclear. All 
other reagents were analytical grade, or the best commercially 
available. 
Table 1 
Preparation of washed platelets from healthy volunteers, and 
pre-labelling with 32P-orthophosphate were performed as 
described [6]. Samples (0.5 ml) of 3*Pi-labelled platelets were 
then placed in aggregometer tubes at 37”C, while stirring, in a 
Elvi aggregometer, in the presence of 1 mM ATP, 0.1 mM 
DTT, and 80 units of erythrocyte, or skeIeta1 muscle 
acylphosphatase (-SH form). After 1 min, saponin was added, 
and incubation was carried out for 2 min. Extraction and 
separation of inositol phospholipids on thin-layer 
chromatography (TLC) plates were performed as described 
[6,7]. In some experiments, samples of ‘*Pi-1abelled platelets 
were analyzed by polyacrylamide gel electrophoresis, perform- 
ed according to Laemmli [ 151, using a 11% polyacrylamide con- 
tinuous gel. Radioactivity of the bands was evidenced by 
autoradiography. In another set of experiments, designed to 
study the effect of acylphosphatase on PIP2 in vitro, 37.5 pg of 
PIP2, or 37.5 pg of PIP2 plus 0.375 &i of [3H]PIP2 were 
dissolved in chloroform and the solvent was evaporated with a 
stream of Nz. The residue was dissolved in 0.5 ml of 50 mM 
Hepes, pH 7.4, containing 1 mM MgCl2, or in 50 mM acetate 
buffer, pH 5.3, containing 1 mM MgClz. The incubation of the 
sonicated solutions with human skeletal muscle 
acylphosphatase (100 units) was carried out at room 
temperature for 15 min, and stopped by addition of 2 ml of a 
solution of chloroform/methanol/HCl (100:200: 2, v/v). The 
polyphosphoinositides were then separated and identified as 
previously described [7]. 
Effect of acylphosphatases and calcium on inositol lipid levels 
in permeabilized human platelets 
Treatment PIP2 PIP PI 
None 5226 + 38 10450 + 741 6257 + 225 
HSM-AP 4668 k 90; 6555 + 348* 7239 + 164* 
E-AP 4969 + 28’ I3495 + 176* 6707 + 97 
Ca*+ 1201 + 107’ 2612 + 128* 7408 + 112* 
Washed human platelets, pre-labelled with “Pi, were treated 
with 20pg/ml of saponin, and with human skeletal muscle 
acylphosphatase (HSM-AP), erythrocyte acylphosphatase (E- 
AP), or Cazf (500/M) for 2 min. Phosphoinositides were 
extracted and separated on thin-layer chromatography plates. 
PIP2, phosphatidylinositol 4,5-bisphosphate; PIP, 
phosphatidylinositol 4-monophosphate; PI, 
phosphatidylinositol. Results, expressed as cpm, are means + 
SE of six replicate samples in a single experiment, one out of six 
that gave almost identical results. Statistical significance was 
assessed by Student’s t-test. * P < 0.02 versus control (no 
addition). Control experiments have shown that addition of 
saponin alone does not affect the metabolism of inositol lipids, 
in agreement with previous reports [6,7] 
3. RESULTS AND DISCUSSION 
We have determined acylphosphatase content in 
human platelets by a non-competitive enzyme- 
linked immunoadsorbent assay (ELISA) carried 
out with polyclonal anti-(erythrocyte acylphos- 
phatase) antibodies [ 121. Acylphosphatase content 
determination by this method resulted in 23.15 f 
0.74 ng/mg protein (mean & SE, n = 3). 
that the effect of the muscular isoenzyme seemed 
more pronounced. Addition of acylphosphatases 
to intact platelets did not induce any change in 
platelet aggregation or inositol lipid metabolism 
(not shown). Addition of 500 PM Ca2+ to platelets 
pre-treated with saponin, produced a marked 
dephosphorylation of PIP2 and PIP with a resul- 
tant accumulation of PI. The smaller increase of 
32P radioactivity in PI compared with the loss in 
PIP2 and PIP could be explained by the observa- 
tion that [32P]PI has a specific activity 15 and 30 
times lower than that of PIP2 and PIP, respectively 
[161. 
In order to investigate the role of the enzyme on Alterations in inositol lipid metabolite levels 
platelet inositol lipid metabolism, we have added were not accompanied by any modification of the 
exogenous acylphosphatases to intact and saponin- pattern of platelet protein phosphorylation, as 
permeabilized human platelets. Table 1 shows that determined by SDS-PAGE analysis of samples in- 
addition of acylphosphatases to permeabilized cubated in the presence of 32Pi and treated with 
human platelets caused a modification of saponin, or with saponin and the muscular or the 
polyphosphoinositides level. Both human skeletal erythrocyte acylphosphatase isoenzymes (fig. 1). 
muscle and human erythrocyte isoenzyme pro- The effects reported in table 1 were not due to a 
duced a loss of PIP2 and phosphatidylinositol direct hydrolytic action of acylphosphatases on 
4-monophosphate (PIP), and an increase of PIP2. Indeed, the [3H]PIP2 content in samples 
phosphatidylinositol (PI). The decreased levels of containing this inositol lipid, incubated with the 
PIP2 and PIP with a concomitant increase of PI in- two acylphosphatase isoenzymes, at pH 7.4 and 
dicate phosphomonoesteratic cleavage of the 5.3, was the same as that of controls, as monitored 
phosphates in position 4 and 5 of the inositol moie- by autoradiography of TLC separation of the 
ty of the polyphosphoinositides. It should be noted polyphosphoinositides (table 2). 
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Fig.1. Effect of acylphosphatase and thrombin on protein 
phosphorylation in human platelets prelabelled with “Pi. 
Washed human platelets prelabelled with ‘*Pi were incubated in 
the aggregometer tubes as in table 1. Autoradiography shows 
the “P-1abelled protein separated on an 11% SDS- 
polyacrylamide gel. Each sample is equivalent to 0.015 ml of 
the original 0.5 ml platelet suspension. Lanes: 1,2, control (no 
addition); 3,4, saponin; 5,6, human skeletal muscle 
acylphosphatase plus saponin; 7, thrombin (0.5 units/ml). It is 
worth noting that acylphosphatase does not induce any 
apparent modification in the pattern of protein 
phosphorylation in permeabilized platelets. Thrombin induces 
the phoshorylation of the 20 and 40 kDa proteins which are, 
respectively, the substrates for myosin light chain kinase and 
protein kinase C. 
The results described above indicate that: (i) 
human platelets contain an acylphosphatase isoen- 
zyme as determined by ELISA; (ii) added 
acylphosphatases are able to modify the pattern of 
inositol lipid content in human platelets; (iii) this 
effect is not accompanied by modifications of the 
protein phosphorylation pattern; (iv) this effect is 
not caused by direct hydrolytic action of the two 
isoenzymes on PIP2. 
Previous studies [1,2] have demonstrated that 
acylphosphatase is able to hydrolyze the 
phosphorylated intermediate formed during the 
activity of the Na+,K+- and Ca*+,Mg*+-dependent 
ATPases, the latter in sarcoplasmic reticulum 
vesicles. It is well known that the 
Ca*+,Mg*+-dependent ATPase is also present in 
the dense tubular system [17], that represents one 
of the major Ca*+ stores in platelets; consequently, 
it is conceivable that acylphosphatase might 
catalyze the hydrolysis of the phosphorylated in- 
termediate which is formed during Ca*+ transport 
in the dense tubular system. Indeed, functional 
similarity between the Ca*+,Mg*+ ATPase from 
sarcoplasmic reticulum vesicles and that from 
membrane of the dense tubular system, has been 
demonstrated. Thus, acylphosphatase action on 
the phosphorylated intermediate might raise the 
level of free Ca*+, promoting the phospho- 
monoesteratic cleavage of polyphosphoinositides 
[6,18]. In this regard, it is important to note that 
the protocol for purification of the enzymes, 
described in detail in [3,12,13], excludes the 
possibility of contamination by Ca*+. 
Results shown in table 1 indicate that Ca*+ pro- 
motes a more drastic dephosphorylation of PIP2 
and PIP in comparison to acylphosphatases. 
However, it should be noted that the amount of 
Ca*+ used in those experiments (500 PM) is 
presumably much higher than that possibly raised 
by the action of acylphosphatases on the 
Ca*+,Mg*+-dependent ATPase. 
The amount of acylphosphatases used in the ex- 
periments reported above is higher than that 
physiologically present in human platelets; 
however, it should be considered that, in a 
permeabilized system, one is forced to administer 
large quantities of a compound in order to observe 
an effect. This holds true, as an example, for the 
intracellular Ca*+-mobilizer, inositol (1,4,5)- 
trisphosphate, that has to be administered in the 
15-45 PM range in order to induce platelet activa- 
tion [8]. 
In conclusion, this study demonstrates that 
human platelets do contain an acylphosphatase 
isoenzyme and that acylphosphatase might play a 
role in the metabolism of inositol lipids; the exact 
nature and extent of this involvement require fur- 
ther study. 
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Table 2 
Effect of human skeletal muscle acylphosphatase on phosphatidylinositol4,5-bisphosphate in 
vitro 
pH 5.3 pH 7.4 
Control HSM-AP Control HSM-AP 
[‘HIPIP 78265 + 692 78423 ? 897 70817 + 971 71690 k 1073 
37.5 pg of PIPz, or 37.5 pg of PIP2 plus 0.375 pCi of [3H]PIPz were dissolved in chloroform 
and the solvent was evaporated with a stream of Nz. The residue was dissolved in 0.5 ml of 
50 mM acetate buffer, pH 5.3, containing 1 mM MgClz, or in 50 mM Hepes, pH 7.4, 
containing 1 mM MgC12. Incubation of the sonicated solutions with human skeletal muscle 
acylphosphatase (HSM-AP, 100 units) was carried out at room temperature for 2 h, and 
stopped by addition of chloroform/methanol/HCl (100:200:2, v/v). Inositol phospholipids 
were separated by thin-layer chromatography as described [7]. Results expressed as cpm, are 
means + SE (n = 3). It should be mentioned that 99.7 + 0.02% of the total recovered 
radioactivity was found associated with PIP2 
[91 
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